تقرير
CBM588 Capsules in Combination With Nivolumab and Ipilimumab for the Treatment of Advanced Stage Kidney Cancer
| العنوان: | CBM588 Capsules in Combination With Nivolumab and Ipilimumab for the Treatment of Advanced Stage Kidney Cancer |
|---|---|
| المؤلفون: | City of Hope Medical Center, Miyarisan Pharmaceuticals, Co., Ltd., National Cancer Institute (NCI) |
| المصدر: | Dman N, Meza L, Bergerot P, Alcantara M, Dorff T, Lyou Y, Frankel P, CuY, Ma V, Llamas M, Hsu J, Zeng Z, Salg N, Salg S, Malhotra J, Chawla N, ChehrazRaffle A, MuddasanR, Glece J, Reg L, Trent J, TakahashM, Oka K, HashS, KortylewskM, Hhlander SK, Pal SK. Nolumab plus umab wh or whout le bacterl supplementatn metastat renal cell carcoma: a randomed phase 1 trl. Nat Med. 2022 Apr;28(4):704-712. do 10.1038/s41591-022-01694-6. Epub 2022 Feb 28. Toma Y, eda T, Sakata S, SaruwatarK, Sato R, ama S, JodaT, Akae K, huka S, SaekS, SakagamT. Assoctn of Probt Clostrm butyrum Therapy wh Surval and Response to mune Checkpot Blockade Patnts wh Lung Cancer. Cancer munol Res. 2020 Oct;8(10):1236-1242. do 10.1158/2326-6066.C-20-0051. Epub 2020 Jul 14. Toma Y, Goto Y, Sakata S, amura K, Memura A, Oka K, HayashA, JodaT, Akae K, AnaM, Hamada S, ama S, SaruwatarK, SaekS, TakahashM, eda T, SakagamT. Clostrm butyrum therapy restores the decreased effacy of mune checkpot blockade lung cancer patnts receg proton pump hors. Oncomunology. 2022 May 27;11(1):2081010. do 10.1080/2162402X.2022.2081010. eCollectn 2022. Toma Y, Sakata S, amura K, ama S, JodaT, SaruwatarK, Hamada S, Akae K, AnaM, Fukusa K, TakakA, Tsukamoto H, Goto Y, Motozono C, Sugata K, Satou Y, Ueno T, eda T, SakagamT. Assoctn of Clostrm butyrum Therapy Usg the Le Bacterl Product CBM588 wh the Surval of Patnts wh Lung Cancer Receg Chemomunotherapy Combatns. Cancers (Basel). 2023 Dec 21;16(1):47. do 10.3390/cancers16010047. Paz Del Socorro T, Oka K, Boulard O, TakahashM, Poul LF, HayashA, Chamalard M. The btherapeut Clostrm butyrum MA588 stra potenttes enterotropm of Rorgammat+Treg and PD-1 blockade effacy. Gut Mrobes. 2024 Jan-Dec;16(1):2315631. do 10.1080/19490976.2024.2315631. Epub 2024 Feb 22. An Open-Label, Phase I, Dose-Finding Study of CBM588 in Combination With Nivolumab/Ipilimumab for Patients With Advanced Stage Renal Cell Carcinoma |
| الوصول الحر: | https://clinicaltrials.gov/ct2/show/NCT06399419Test |
| قاعدة البيانات: | ClinicalTrials.gov |
| الوصف غير متاح. |